PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. PLUR, GRCE, STTK, ACRV, KPTI, PEPG, EGRX, ARTV, ITRM, and KLTOShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Pluri (PLUR), Grace Therapeutics (GRCE), Shattuck Labs (STTK), Acrivon Therapeutics (ACRV), Karyopharm Therapeutics (KPTI), PepGen (PEPG), Eagle Pharmaceuticals (EGRX), Artiva Biotherapeutics (ARTV), Iterum Therapeutics (ITRM), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Pluri Grace Therapeutics Shattuck Labs Acrivon Therapeutics Karyopharm Therapeutics PepGen Eagle Pharmaceuticals Artiva Biotherapeutics Iterum Therapeutics Klotho Neurosciences Pluri (NASDAQ:PLUR) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Do analysts recommend PLUR or PHXM? Pluri currently has a consensus target price of $12.00, suggesting a potential upside of 108.70%. Given Pluri's stronger consensus rating and higher possible upside, research analysts clearly believe Pluri is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PLUR or PHXM more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. PHAXIAM Therapeutics' return on equity of 0.00% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% PHAXIAM Therapeutics N/A N/A N/A Do institutionals & insiders hold more shares of PLUR or PHXM? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 25.9% of Pluri shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, PLUR or PHXM? PHAXIAM Therapeutics has lower revenue, but higher earnings than Pluri. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K136.43-$20.89M-$5.53-1.04PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A Does the media favor PLUR or PHXM? In the previous week, Pluri had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for Pluri and 0 mentions for PHAXIAM Therapeutics. Pluri's average media sentiment score of 1.14 beat PHAXIAM Therapeutics' score of 0.00 indicating that Pluri is being referred to more favorably in the media. Company Overall Sentiment Pluri Positive PHAXIAM Therapeutics Neutral Which has more risk & volatility, PLUR or PHXM? Pluri has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. SummaryPluri beats PHAXIAM Therapeutics on 8 of the 13 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$127.96M$5.56B$9.03BDividend YieldN/A3.74%5.22%3.99%P/E RatioN/A3.4027.6920.25Price / SalesN/A4,084.30389.63163.09Price / CashN/A13.1936.8958.10Price / Book0.3942.828.035.67Net Income-$240K-$92.79M$3.18B$249.21M7 Day PerformanceN/A2.49%2.93%3.28%1 Month PerformanceN/A2.58%1.72%3.95%1 Year PerformanceN/A181.40%34.39%20.98% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049PLURPluri3.5586 of 5 stars$5.75+6.7%$12.00+108.7%-4.5%$42.22M$330K-1.04150News CoverageInsider TradeGap DownGRCEGrace Therapeutics1.7644 of 5 stars$3.13+3.6%$12.00+283.4%N/A$41.76MN/A-3.52N/APositive NewsSTTKShattuck Labs2.8547 of 5 stars$0.84-1.4%$7.50+798.2%-77.3%$40.57M$5.72M-0.60100Gap UpACRVAcrivon Therapeutics2.6221 of 5 stars$1.30+0.4%$17.71+1,267.9%-81.7%$40.45MN/A-0.5858KPTIKaryopharm Therapeutics3.8421 of 5 stars$4.62+0.2%$43.20+835.1%-62.4%$39.83M$145.24M-0.35380Positive NewsPEPGPepGen2.9412 of 5 stars$1.22+0.8%$7.67+528.4%-92.8%$39.59MN/A-0.3930EGRXEagle PharmaceuticalsN/A$3.00+3.6%N/A-45.5%$38.96M$257.55M0.00100Gap DownARTVArtiva Biotherapeutics2.2305 of 5 stars$1.65+3.5%$17.80+982.1%N/A$38.74M$250K0.0081ITRMIterum Therapeutics1.8962 of 5 stars$0.95-1.8%$9.00+846.4%-17.3%$38.72MN/A-0.9610News CoverageKLTOKlotho NeurosciencesN/A$1.14-4.2%N/AN/A$38.67MN/A-3.17N/AAnalyst Upgrade Related Companies and Tools Related Companies Pluri Competitors Grace Therapeutics Competitors Shattuck Labs Competitors Acrivon Therapeutics Competitors Karyopharm Therapeutics Competitors PepGen Competitors Eagle Pharmaceuticals Competitors Artiva Biotherapeutics Competitors Iterum Therapeutics Competitors Klotho Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHXM Stock Alerts